Therapeutic Options for Patients With Multiple Myeloma in the Second Line and Beyond

Selinexor-Based Triplet Shines in Patients With PI-Naive Myeloma

Binod Dhakal, MD, discusses the extended follow-up of combination selinexor in the proteasome inhibitor–naive subgroup of patients with multiple myeloma.

Evaluating the Efficacy in the BOSTON Trial for Multiple Myeloma

Binod Dhakal, MD, discusses the BOSTON trial of selinexor combination therapy in patients with relapsed/refractory multiple myeloma.

Considering the Uses of Myeloma Treatments After Relapse

Binod Dhakal, MD, discusses using a variety of combination therapies as bridging or later-line options for patients with relapsed myeloma.

Lack of Comparative Trials in R/R MM Complicates Treatment Selection

Selinexor Shows Potential Role in PI-Naive Relapsed Multiple Myeloma

During a live event, Binod Dhakal, MD, and participants discussed their experience using selinexor in the second line and beyond in patients with multiple myeloma.

Considering Ways to Optimize Weekly Selinexor Dosing for Myeloma

During a live event, Jack Khouri, MD, discusses selinexor-based therapies for relapsed multiple myeloma, emphasizing AE management and weekly dosing.

Selinexor Triplet Reviewed as Second-Line Option in Multiple Myeloma

During a Case-Based Roundtable® event, Jack Khouri, MD, looked at selinexor trial data for a patient with relapsed/refractory multiple myeloma in the first article of a 2-part series.

Lower-Dose Selinexor Data Lead to Patient Selection Questions in RRMM

During a Case-Based Roundtable® event, Jonathan L. Kaufman, MD, discussed which lines of therapy and at what doses would be appropriate to use selinexor in a patient with relapsed/refractory multiple myeloma in the second article of a 2-part series.

Age, Disease Burden Are Factors in Early Use of Selinexor in Multiple Myeloma

During a Case-Based Roundtable® event, Jonathan L. Kaufman, MD, discussed treatment approaches and the tolerability of a selinexor-containing regimen in a patient with relapsed/refractory multiple myeloma in the first article of a 2-part series.

Handling GI Toxicities While Using Selinexor Triplet Therapy in RRMM

Adam Binder, MD, discusses how to handle gastrointestinal toxicities for patients with relapsed/refractory multiple myeloma who are on the triple therapy of selinexor, bortezomib, and dexamethasone.

Notable Outcomes of Selinexor-Based Triplet Therapy Addressed in RRMM

Adam Binder, MD, discusses what he found to be notable from the results of the phase 3 BOSTON trial that looked at the efficacy of selinexor, bortezomib, and dexamethasone triplet therapy for patients with relapsed/refractory multiple myeloma.

Selinexor-Based Triplet Shows Tolerability With Dose Reductions in RRMM

In the second article of a 2-part series, Sumit Madan, MD, talked about the manageable toxicity profile with the triplet therapy selinexor (Xpovio), bortezomib, and dexamethasone and how dose reductions led to tolerable outcomes in patients with relapsed/refractory multiple myeloma.

Selinexor-Based Triplet Therapy Improves Outcomes in Certain Patients with RRMM

In the first article of a 2-part series, Sumit Madan, MD, discusses how the combination of selinexor, bortezomib, and dexamethasone shows superior survival outcomes for patients with relapsed/refractory multiple myeloma that are proteasome inhibitor naive or have high-risk cytogenetics.

Supportive Care Methods in Later Lines of Therapy in RRMM

In the second article of a 2-part series, Jack Khouri, MD, discusses with a group of physicians what supportive care options, such as anti-nausea medicine and dose modifications, are important when treating a patient with relapsed/refractory in the third-line setting and beyond.

Physicians Discuss Supportive Care Practices in R/R Multiple Myeloma

In the first article of a 2-part series, Jack Khouri, MD, discussed the challenges that come with the toxicity profile of selinexor and how physicians can manage these adverse events.

Counseling Patients on Treatment With Selinexor for Multiple Myeloma

During a Targeted Oncology™ Case-Based Roundtable™ event, Ariel F. Grajales-Cruz, MD, and other physicians discussed how to manage toxicities and counsel patients when using selinexor for relapsed/refractory multiple myeloma.

Physicians Discuss Options for Second Relapse in Multiple Myeloma

During a Targeted Oncology™ Case-Based Roundtable™ event, Ariel F. Grajales-Cruz, MD, discussed the case of a patient who relapsed after receiving first- and second-line regimens for multiple myeloma. This is the first of 2 articles based on this event.

Managing Adverse Events With Selinexor in R/R Multiple Myeloma

During a Targeted Oncology™ Case-Based Roundtable™ event, Sumit Madan, MD, discussed with participants what challenges they face using selinexor in patients with relapsed/refractory multiple myeloma. This is the second of 2 articles based on this event.

Physicians Discuss Recommended Therapies for R/R Multiple Myeloma

During a Targeted Oncology™ Case-Based Roundtable™ event, Sumit Madan, MD, and participants discussed the therapies listed on the National Comprehensive Cancer Network guidelines for patients with relapse after 1 or more prior lines of therapy. This is the first of 2 articles based on this event.

Dosing Considerations for Selinexor in R/R Multiple Myeloma

During a Targeted Oncology™ Case-Based Roundtable™ event, Joshua Richter, MD, discussed considerations when using selinexor with various drug combinations in later-line multiple myeloma therapy. This is the second of 2 articles based on this event.

BOSTON Trial Shows Efficacy of Selinexor in R/R Multiple Myeloma

During a Targeted Oncology™ Case-Based Roundtable™ event, Joshua Richter, MD, discussed the results of the BOSTON trial of selinexor in patients with relapsed/refractory multiple myeloma.